Highlights of ASCO: Hodgkin’s Lymphoma S1826 Study

1 year ago

By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center   Hodgkin’s lymphoma (HL) has had an exciting and…

Updates at ASCO: The Phase 3 IMerge Study

1 year ago

Imetelstat in low-risk MDS for transfusion independence   By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center  …

Highlights of ASCO: MDS COMMANDS Study

1 year ago

By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center   Low-risk MDS had many exciting updates, starting with…

ASCO23 – LUNAR Study Summary

1 year ago

Author: Lei Deng, MD Roswell Park Comprehensive Cancer Center   Live report from ASCO23, Chicago, IL June 6, 2023  …

ASCO23 – WU-KONG6 Trial Summary

1 year ago

Author: Lei Deng, MD Roswell Park Comprehensive Cancer Center   Live report from ASCO23, Chicago, IL June 6, 2023  …

Updates from ASCO – Results from the PALMIRA Study

1 year ago

Palbociclib after progression on Palbociclib in HR-positive HER2-negative breast cancer does not show improvement in progression-free survival   By Dr.…

Updates from ASCO2023 – The SONIA Trial

1 year ago

By Dr. Arya Miriam Roy & Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center   The CDK 4/6 inhibitors…

Updates from ASCO23 – ADAURA Trial Plenary Lecture

1 year ago

Author:  Lei Deng, MD PGY-6 Fellow Of Hematology/Oncology – Roswell Park Comprehensive Cancer Center, Buffalo, NY.  Incoming Assistant Professor At UW/Fred Hutch,…

My Take On KEYNOTE-671: ASCO23 June 3, 2023

1 year ago

Author:  Lei Deng, MD PGY-6 Fellow of Hematology/Oncology - Roswell Park Comprehensive Cancer Center, Buffalo, NY.  Incoming Assistant Professor at UW/Fred Hutch,…

Adjuvant Ribociclib and Endocrine Therapy in Patients with HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial

1 year ago

By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center   Findings from the MonarchE clinical trial1 led to the…